Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Core Insights - Corbus Pharmaceuticals Holdings, Inc. is focused on advancing its clinical programs in oncology and obesity, with significant data readouts expected in the second half of 2025 [2][7]. Corporate and Program Updates - The company is progressing with three clinical programs: CRB-701, CRB-913, and CRB-601, all of which are on track for data readouts in the latter half of 2025 [7]. - CRB-701 is a next-generation antibody drug conjugate targeting Nectin-4, with a precise drug antibody ratio of 2 and utilizing monomethyl auristatin E (MMAE) as the payload [3]. - CRB-913 is designed as a peripherally restricted oral small molecule CB1 receptor inverse agonist for obesity treatment, aiming to minimize neuropsychiatric risks associated with previous drugs in this class [4]. - CRB-601 is an anti-αvβ8 integrin monoclonal antibody targeting TGFβ activation in the tumor microenvironment, with dose escalation data expected in Q4 2025 [5]. Financial Results - For the quarter ended June 30, 2025, the company reported a net loss of approximately $17.7 million, compared to a net loss of $10.0 million for the same period in 2024 [9]. - Operating expenses increased by $8.2 million to approximately $19.2 million, primarily due to higher clinical development costs [10]. - As of June 30, 2025, the company had $116.6 million in cash and investments, sufficient to fund operations through Q2 2027 based on planned expenditures [10].